AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Therapeutic Vaccine To Start Testing In Phase II Study.(AVANT Immunotherapeutics Inc. to test CETi-1 cholesterol management vaccine)
2001 SEP 19 - (NewsRx.com & NewsRx.net) --
AVANT Immunotherapeutics, Inc. announced today the start of a placebo-controlled Phase II study of its cholesterol management vaccine (CETi-1) in approximately 200 patients with low levels of HDL (high-density lipoprotein) cholesterol.
The objectives of the study are to evaluate the safety, immunogenicity, and dose-response relationship of the CETi-1 product in patients who receive an initial immunization followed by boosters. The principal endpoint is the change in HDL cholesterol measured after the six-month booster.
The study is being conducted at the Chicago Center for Clinical Research and Rush-Presbyterian-St. Luke's Medical Center under the supervision of principal investigator Dr. Michael Davidson, a leading authority on cholesterol metabolism.
CETi-1 is designed to raise serum HDL cholesterol levels by blocking the transfer of cholesterol from HDL to LDL (low-density lipoprotein). HDL (often referred to as good cholesterol) acts to protect against atherosclerosis while LDL (often referred to as bad cholesterol) acts to promote atherosclerosis. CETi-1 induces antibodies against a portion of the serum protein responsible for this transfer, cholesteryl ester transfer protein (CETP). Atherosclerosis is an underlying cause of ...
- Results of a Phase I and Extension Study of AVANT Immunotherapeutics' Novel...
- Press release article from: Business Wire July 17, 2003 700+ words
...to raising HDL cholesterol under development by AVANT Immunotherapeutics (Nasdaq...protective HDL cholesterol - a need...Officer of AVANT Immunotherapeutics. She commented...increases in HDL cholesterol at the highest...
- AVANT Immunotherapeutics Announces Positive Phase II Trial Results of Its...
- Press release article from: Business Wire October 22, 2003 700+ words
...Oct. 22, 2003 AVANT Immunotherapeutics, Inc. (Nasdaq...an increase in HDL-cholesterol from baseline in...the increase in HDL-cholesterol from baseline was...to raise serum HDL cholesterol levels by blocking...of therapy." AVANT Immunotherapeutics is ...
- Avant Immunotherapeutics Receives Key Patent for Its Cholesterol Management...
- Press release article from: Business Wire June 25, 2002 700+ words
...Writers BIOWIRE2K AVANT Immunotherapeutics, Inc. (Nasdaq...density lipoprotein (HDL) cholesterol to low-density...heart-protective HDL cholesterol to rise. This...drug market, low HDL cholesterol is an important...western world. AVANT Immunotherapeutics, ...
- AVANT Immunotherapeutics Receives NIH SBIR Phase 2 Award for Development and...
- Press release article from: Business Wire September 27, 2006 700+ words
...NEEDHAM, Mass. -- AVANT Immunotherapeutics, Inc. (NASDAQ...Executive Officer of AVANT Immunotherapeutics, Inc. "This funding...immune responses. About AVANT Immunotherapeutics, Inc. AVANT Immunotherapeutics...
- AVANT Immunotherapeutics Receives Additional Key Patent for Its Cholesterol...
- Press release article from: Business Wire April 29, 2003 700+ words
...April 29, 2003 AVANT Immunotherapeutics, Inc. (Nasdaq: AVAN...LDL and thus causing HDL cholesterol levels to rise. A Phase...patients with low initial HDL cholesterol, is nearing completion...promote atherosclerosis. AVANT Immunotherapeutics is engaged in the ...
- AVANT Immunotherapeutics to Demand Immediate Delisting from Berlin-Bremen Stock...
- Press release article from: Business Wire July 28, 2004 700+ words
...NEEDHAM, Mass. -- AVANT Immunotherapeutics, Inc. (Nasdaq...vaccine candidate." AVANT Immunotherapeutics, Inc. discovers...Additional information on AVANT Immunotherapeutics, Inc. can be obtained...
- New Research Illustrates Role of CETP in Atherosclerosis; Supports Concept Of...
- Press release article from: PR Newswire November 29, 1999 700+ words
...development by AVANT Immunotherapeutics, Inc. (Nasdaq...raise serum HDL cholesterol levels by inducing...Officer of AVANT Immunotherapeutics. In preliminary...of Health. AVANT Immunotherapeutics, Inc., is...
- In- Depth Research on AVANT Immunotherapeutics Inc.
- Press release article from: M2 Presswire June 27, 2007 700+ words
...News: In- Depth Research on AVANT Immunotherapeutics Inc(C)1994-2007 M2 COMMUNICATIONS...27062007 In- Depth Research on AVANT Immunotherapeutics Inc (NASDAQ:AVAN) AVANT Immunotherapeutics, Inc. discovers and develops...
Source: HighBeam Research, Therapeutic Vaccine To Start Testing In Phase II Study.(AVANT...